G. Rousseau-Bussac

Hôpital Intercommunal de Créteil — France

Medicine · Health Sciences

8h-index290citations64works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(42), Lung Cancer Research Studies(21), Lung Cancer Diagnosis and Treatment(16), Cancer Immunotherapy and Biomarkers(10), Pancreatic and Hepatic Oncology Research(7)

Publications64 total

Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
The Lancet Respiratory Medicine·2025· 5 citedOpen Access
An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
Journal of Clinical Oncology·2025
Evaluation of teleguided high-intensity exercise rehabilitation at home before lung-cancer surgery (PREPACHIR Study)
Lung Cancer·2025· 1 cited
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study
Targeted Oncology·2025· 1 citedOpen Access
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study
European Journal of Cancer·2025· 1 citedOpen Access
Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report
Translational Lung Cancer Research·2025Open Access
Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report
Translational Lung Cancer Research·2024· 2 citedOpen Access
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)
Lung Cancer·2024· 5 citedOpen Access
Efficacité et tolérance du sotarasib chez les patients porteurs d’un cancer bronchique non à petites cellules avec une mutation KRAS G12 C : résultats de l’étude en vie réelle IFCT-2102 Lung KG12Ci
Revue des Maladies Respiratoires Actualités·2024
Real-World Effectiveness and Tolerability of Sotorasib in Patients with Kras G12c-Mutated Metastatic Non-Small Cell Lung Cancer: The Ifct-2102 Lung Kg12ci Study
SSRN Electronic Journal·2024Open Access
Deux cas d’hyperprogressions de mésothéliomes pleuraux sous inhibiteurs des checkpoints
Revue des Maladies Respiratoires Actualités·2024
DOULAPLUX : efficacité de l’anesthésie locale à la xylocaïne tamponnée (AL) dans le contrôle de la douleur induite par les gestes pleuraux
Revue des Maladies Respiratoires Actualités·2024
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
Targeted Oncology·2023· 3 cited
Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019).
Journal of Clinical Oncology·2023· 1 cited
ICU admission for solid cancer patients treated with immune checkpoint inhibitors
Annals of Intensive Care·2023· 17 citedOpen Access
Erratum to “When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study” [Bull. Cancer 109 (2022) 916–24]
Bulletin du Cancer·2023
Explore-ALK : étude de cohorte prospectif non interventionnelle, nationale et multicentrique de patients atteints de cancer bronchopulmonaire non à petites cellules caractérisés par un réarrangement ALK. Caractéristiques cliniques et biologiques des 100 premiers patients de la cohorte
Revue des Maladies Respiratoires Actualités·2023
Impact des rebiopsies chez les patients atteints de Cancer Bronchique Non à Petites Cellules de stade IIIB/IV avec addiction oncogénique (EGFR/ROS/ALK) progressant après thérapie ciblée orale
Revue des Maladies Respiratoires Actualités·2023
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
Targeted Oncology·2022· 16 cited
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study
Bulletin du Cancer·2022· 8 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

C. Chouaïd(34), Florian Guisier(13), I. Monnet(11), R. Descourt(10), Marie Wislez(9), L. Jabot(9), J.B. Auliac(8), Roland Schött(7), Perrine Créquit(7), F. Viñas(7), Alexis B. Cortot(6), Rémi Veillon(6), C. Decroisette(6), V. Gounant(5), M. Pérol(5), David Planchard(5), B. Mennecier(5), Loïck Galland(5), Éric Dansin(5), Jennifer Arrondeau(5)